Recent Advances in the Management of Adverse Events Associated with Lorlatinib

被引：1

作者：

Liao, Dehua ^{[1
]}

Zhang, Jiwen ^{[1
,2
]}

Yan, Ting ^{[1
]}

Chen, Shanshan ^{[1
]}

Li, Wei ^{[1
]}

Shangguan, Dangang ^{[1
]}

She, Zhihua ^{[3
]}

机构：

[1] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Pharm, Changsha, Peoples R China

[2] Univ South China, Sch Pharm, Hengyang, Peoples R China

[3] Hunan Prov Maternal & Child Hlth Care Hosp, Dept Med Adm, Changsha, Peoples R China

来源：

ONCOTARGETS AND THERAPY | 2023年 / 16卷

关键词：

ALK; lorlatinib; adverse event; NSCLC; therapy management; CELL LUNG-CANCER; ALK; INHIBITOR; EFFICACY; SAFETY; PENETRANT; ROS1;

D O I：

10.2147/OTT.S426989

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on firstand second-generation TKIs. In comparison with other ALK-TKIs, lorlatinib has a unique safety profile for hyperlipidemia and central nervous system adverse events. Lorlatinib-induced adverse events are well tolerated, permanent discontinuations are rarely reported, and dose modifications and/or standard medical therapy are useful for the management of adverse events. Our present study reviews the safety profile of lorlatinib as well as the relevant management strategies. Our present study aims to provide a practical guide for the scientific management and application of lorlatinib.

引用

页码：731 / 738

页数：8

共 50 条

[1] Podcast on the Management of Adverse Events Associated with Lorlatinib
Todd M. Bauer
Erin M. Bertino
[J]. Advances in Therapy, 2022, 39 : 1447 - 1456
[2] Podcast on the Management of Adverse Events Associated with Lorlatinib
Bauer, Todd M.
Bertino, Erin M.
[J]. ADVANCES IN THERAPY, 2022, 39 (04) : 1447 - 1456
[3] Clinical Management of Adverse Events Associated with Lorlatinib
Bauer, Todd M.
Felip, Enriqueta
Solomon, Benjamin J.
Thurm, Holger
Peltz, Gerson
Chioda, Marc D.
Shaw, Alice T.
[J]. ONCOLOGIST, 2019, 24 (08): : 1103 - 1110
[4] A pragmatic guide for management of adverse events associated with lorlatinib
Liu, Geoffrey
Mazieres, Julien
Stratmann, Jan
Ou, Sai-Hong Ignatius
Mok, Tony
Grizzard, Mary
Goto, Yasushi
Felip, Enriqueta
Solomon, Benjamin J.
Bauer, Todd M.
[J]. LUNG CANCER, 2024, 191
[5] CONSENSUS RECOMMENDATIONS FOR MANAGEMENT AND COUNSELING OF ADVERSE EVENTS ASSOCIATED WITH LORLATINIB
Hronek, Jan W.
Kettle, Jacob K.
Jamil, Ahsan
Devgan, Geeta
Chioda, Marc D.
Reed, Mollie
[J]. ONCOLOGY NURSING FORUM, 2019, 46 (02)
[6] Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners
Mollie Reed
Aimee-Lauren S. Rosales
Marc D. Chioda
Lindsey Parker
Geeta Devgan
Jacob Kettle
[J]. Advances in Therapy, 2020, 37 : 3019 - 3030
[7] Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners
Reed, Mollie
Rosales, Aimee-Lauren S.
Chioda, Marc D.
Parker, Lindsey
Devgan, Geeta
Kettle, Jacob
[J]. ADVANCES IN THERAPY, 2020, 37 (06) : 3019 - 3030
[8] Neurocognitive Adverse Events of Lorlatinib: On the Way to Precise Prediction?
Jia, Keyi
Ren, Shengxiang
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 26 - 28
[9] Recent advances in the understanding and management of severe cutaneous adverse reactions
Adler, N. R.
Aung, A. K.
Ergen, E. N.
Trubiano, J.
Goh, M. S. Y.
Phillips, E. J.
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 23 - 23
[10] Management of Carfilzomib-Associated Cardiac Adverse Events
Mikhael, Joseph
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (05): : 241 - 245

← 1 2 3 4 5 →